zoledronic acid has been researched along with docetaxel anhydrous in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (38.46) | 29.6817 |
| 2010's | 40 (51.28) | 24.3611 |
| 2020's | 8 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Potter, DM | 1 |
| Crispino, J; Fraterrigo, T; Green, J; Lipton, A; Witters, LM | 1 |
| Abbou, CC; Allory, Y; Chopin, D; de la Taille, A; Hoznek, A; Paule, B; Salomon, L; Vacherot, F; Vordos, D; Yiou, R | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M | 1 |
| Higano, CS | 2 |
| Harmenberg, U; Hjelm-Eriksson, M; Kälkner, KM; Lennartsson, L; Lennernäs, B; Nilsson, S; Ullén, A | 1 |
| Brown, LG; Brubaker, KD; Corey, E; Vessella, RL | 1 |
| Albers, P; Börgermann, C; Miller, K; Thüroff, J; Wirth, M | 1 |
| Avcu, F; Ural, AU | 1 |
| Fosså, SD; Hernes, E; Lilleby, W; Raabe, N; Waehre, H | 1 |
| Tombal, B | 1 |
| Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G | 1 |
| Salciccia, S; Sciarra, A | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
| Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC | 1 |
| Copeman, M; Gurney, H; Rosenthal, MA; Woo, H; Zingarelli, G | 1 |
| Miki, T; Okihara, K | 1 |
| Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL | 1 |
| Asakura, T; Fujinami, K; Goto, A; Jinza, S; Okajima, K; Onuki, T; Senga, Y; Yamashita, Y | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR | 2 |
| Daignault, S; Dunn, RL; Escara-Wilke, J; Friedman, J; Ignatoski, KM; Keller, ET; Smith, DC; Zhang, X | 1 |
| Atmaca, H; Baran, Y; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S | 1 |
| Argonza-Aviles, E; Ericson, SG; Gajra, A; Pandya, KJ; Warsi, GM; Wozniak, AJ | 1 |
| Clarke, NW; Dearnaley, DP; James, ND; Mason, MD; Morgan, RC; Parmar, MK; Royston, P; Sanders, K; Sydes, MR | 1 |
| Gupta, NP; Nayyar, R; Sharma, N | 1 |
| Yuasa, T | 1 |
| Bi, Y; Cao, C; Ehirchiou, D; Gao, Y; Kikuiri, T; Le, A; Shi, S; Zhang, L | 1 |
| Bochicchio, AM; Budillon, A; Caraglia, M; Catalano, A; Facchini, G; Ferrari, E; Gentilini, D; Iaffaioli, RV; Leopardo, D; Marra, L; Marra, M; Morabito, A; Nasti, G; Perrone, F; Piccirillo, MC; Striano, S; Tortoriello, A; Vitale, G | 1 |
| Kumar, A; Manjappa, AS; Megraj Khandelwal, VK; Mishra, AK; Monkkonen, J; Ramachandra Murthy, RS; Ramanlal Chaudhari, K; Ukawala, M | 1 |
| Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M | 1 |
| Goto, K; Kubota, K; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K | 1 |
| Penson, DF; Resnick, MJ | 1 |
| Bulbul, MA; Elias, E; Farhat, FS; Khauli, RB; Saleh, A; Shamseddine, A | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Coleman, RE; Cross, SS; Evans, A; Freeman, JV; Hatton, MQ; Holen, I; Ingram, CE; Jolley, IJ; Mori, S; Syddall, SP; Wilson, C; Winter, MC | 1 |
| Fujimoto, N; Fukumoto, R; Hayashi, T; Koide, T; Oka, D; Soda, T | 1 |
| D'Amico, AV | 1 |
| Charehbili, A; Dercksen, M; Hamdy, NA; Heijns, JB; Kessels, L; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JW; Pepels, MJ; Putter, H; Smit, VT; van de Velde, CJ; van de Ven, S; van Laarhoven, HW; van Leeuwen-Stok, AE; van Warmerdam, LJ; Vriens, B; Wasser, MN | 1 |
| Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T | 1 |
| Charehbili, A; Kroep, JR; Liefers, GJ; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Smit, VT; van de Velde, CJ; van Leeuwen-Stok, AE; Wasser, MN | 1 |
| Chen, W; Jin, H; Pan, Y; Wang, F; Weng, Z; Ye, T; Yu, Z; Zheng, Y | 1 |
| Atmaca, H; Degirmenci, M; Karaca, B; Kisim, A; Sanli, UA; Sezgin, C; Uslu, R; Uzunoglu, S; Varol, U | 1 |
| Bertelli, G; Jones, RM; Morgan, C | 1 |
| Gao, D; Gao, L; Jia, B; Liu, Z; Sun, X; Wang, F; Yu, X; Zhang, C | 1 |
| Albiges, L; Burdett, S; Clarke, NW; Fisher, D; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LHM; Sweeney, CJ; Sydes, MR; Tierney, JF; Tombal, B; Vale, CL | 1 |
| Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, LJ; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Daunton, A; Goranitis, I; Hussain, S; James, ND; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, SJ; Pope, AM; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Scher, HI | 1 |
| Assi, T; Bachour, M; El Rassy, E; Farhat, F; Ghosn, M; Kattan, J | 1 |
| Sternberg, CN | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Taneja, SS | 1 |
| Fu, P; Li, Q; Wen, F; Yang, Y; Zhang, P | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Hamid, AA; Sweeney, CJ | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Aragon-Ching, JB; Finianos, A | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| George, DJ | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Griebling, TL | 1 |
| Akpa, AA; Bathily, M; Berthe, D; Cisse, HL; Dao, S; Dembele, JP; Diabate, K; Diakite, A; Diallo, DA; Diarra, B; Diarra, IM; Fofana, Y; Guindo, I; Konate, M; Kone, AA; Kone, AC; Kone, AS; Kone, J; Minta, D; Ouattara, BZ; Sidibe, A; Sidibe, FM; Sidibe, S; Soumare, MD; Toloba, Y; Toure, BA | 1 |
| Cheng, Y; Ji, QF; Liu, DZ; Liu, M; Mei, QB; Yang, Q; Zhou, SY | 1 |
| Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Bratt, O; Carlsson, S; Fransson, P; Karlsson, CT; Kindblom, J; Stranne, J | 1 |
| Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S | 1 |
13 review(s) available for zoledronic acid and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current status of treatment for patients with metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Docetaxel; Drug Monitoring; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2005 |
[Therapeutic options for hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Practice Patterns, Physicians'; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
[Treatment of hormone-resistant prostate cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Decompression, Surgical; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoporosis; Practice Guidelines as Topic; Prognosis; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Zoledronic Acid | 2007 |
[Strategy in advanced castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid | 2012 |
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Survival Rate; Taxoids; Zoledronic Acid | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Zoledronic acid for the treatment of prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
[Gastrointestinal symptoms revealing COVID-19 in Malian breast cancer patient undergoing chemotherapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Betacoronavirus; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Coronavirus Infections; COVID-19; Diarrhea; Docetaxel; Fatal Outcome; Female; HIV Infections; Humans; Liver Neoplasms; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spinal Neoplasms; Tomography, X-Ray Computed; Vomiting; Zoledronic Acid | 2020 |
21 trial(s) available for zoledronic acid and docetaxel anhydrous
| Article | Year |
|---|---|
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2004 |
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2009 |
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; United States; Zoledronic Acid | 2010 |
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
Topics: Androgen Antagonists; Antineoplastic Agents; Data Interpretation, Statistical; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Software; Taxoids; Zoledronic Acid | 2009 |
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Fever; Humans; Imidazoles; Infusions, Intravenous; Interleukin-8; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neutropenia; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2010 |
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2012 |
High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Kallikreins; Kaplan-Meier Estimate; Lebanon; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Zoledronic Acid | 2013 |
Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follistatin; Humans; Imidazoles; Inhibins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Time Factors; Transforming Growth Factor beta1; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease-Free Survival; Docetaxel; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2014 |
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Taxoids; Treatment Outcome; Tumor Burden; Zoledronic Acid | 2014 |
Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Strontium; Taxoids; Zoledronic Acid | 2016 |
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphosphonates; Docetaxel; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid | 2016 |
44 other study(ies) available for zoledronic acid and docetaxel anhydrous
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Camptothecin; Carboplatin; Clinical Trials, Phase I as Topic; Computer Simulation; Dexamethasone; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Maximum Tolerated Dose; Monte Carlo Method; Paclitaxel; Taxoids; Zoledronic Acid | 2002 |
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diphosphonates; Docetaxel; Genes, erbB-2; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Taxoids; Transfection; Zoledronic Acid | 2003 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Mitosis; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2005 |
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Random Allocation; Taxoids; Tibia; Transplantation, Heterologous; Zoledronic Acid | 2006 |
Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Synergism; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Docetaxel and beyond.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?
Topics: Antineoplastic Agents; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Death of a clinical trial: a speculative inclusion criterion gone wrong.
Topics: Antineoplastic Agents; Australia; Chemotherapy, Adjuvant; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Zoledronic Acid | 2007 |
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Everolimus; Humans; Imidazoles; Male; Mice; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Zoledronic Acid | 2008 |
[A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2008 |
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid | 2008 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid | 2008 |
Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Diphosphonates; DNA Fragmentation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Zoledronic Acid | 2009 |
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Remodeling; Dexamethasone; Diphosphonates; Docetaxel; Humans; Imidazoles; Jaw Diseases; Mandible; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Osteocytes; Osteonecrosis; Taxoids; Zoledronic Acid | 2010 |
[Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2010 |
New treatment options for patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Carriers; Humans; Imidazoles; Lactic Acid; Mice; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Zoledronic Acid | 2012 |
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
[Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drainage; Fatal Outcome; Humans; Imidazoles; Jaw; Male; Prostatic Neoplasms; Retropharyngeal Abscess; Taxoids; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2015 |
Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Diphosphonates; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Prostatic Neoplasms; ras Proteins; rhoA GTP-Binding Protein; Taxoids; Zoledronic Acid | 2015 |
Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Female; Imidazoles; Lectins, C-Type; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Receptors, Cell Surface; Sensitivity and Specificity; Spectroscopy, Near-Infrared; Taxoids; Zoledronic Acid | 2015 |
Defining new standards of care for men with prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2016 |
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2016 |
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2016 |
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Docetaxel; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Standard of Care; Taxoids; Zoledronic Acid | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Prostate cancer: A new standard-of-care for advanced-stage disease.
Topics: Docetaxel; Humans; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid | 2017 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer.
Topics: Antineoplastic Agents; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Male; Nanoparticles; Polymers; Prostatic Neoplasms; Zoledronic Acid | 2021 |
Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center.
Topics: Adult; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Zoledronic Acid | 2022 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Denosumab; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sweden; Zoledronic Acid | 2022 |
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2023 |